Quantum Biopharma (QNTM) Common Equity (2020 - 2026)

Quantum Biopharma's Common Equity history runs 7 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 131.35% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$1.4 million (down 131.35% YoY), while the FY2025 annual figure was $5.1 million, down 51.13% from the prior year.
• Common Equity came in at -$1.4 million for Q1 2026 at Quantum Biopharma, down from $5.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $148.9 million in Q3 2024 to a low of -$1.4 million in Q1 2026.
• A 5-year average of $23.1 million and a median of $8.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity decreased 19.13% in 2024 and sank 131.35% in 2026, its largest moves.
• Quantum Biopharma's Common Equity stood at $30.5 million in 2022, then sank by 57.73% to $12.9 million in 2023, then fell by 19.13% to $10.4 million in 2024, then slumped by 51.13% to $5.1 million in 2025, then slumped by 127.83% to -$1.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$1.4 million, $5.1 million, and $7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison